Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
266.59
-14.90 (-5.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
Next >
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
Today 8:00 EDT
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
October 30, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
October 17, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
October 16, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
October 09, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
September 29, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast TTR Investor Day
September 26, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
September 12, 2024
Alnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug.
Via
MarketBeat
Exposures
Product Safety
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
August 30, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
August 28, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
August 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
August 01, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
July 18, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
June 24, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Issues 2023 Corporate Responsibility Report
May 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
May 02, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
April 18, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
April 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
March 20, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
March 13, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
March 05, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
February 27, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
February 15, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
January 29, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
January 09, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
January 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
December 13, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
3 biotech powerhouses poised to thrive amid sector rebound
December 08, 2023
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.
Via
MarketBeat
Topics
ETFs
Alnylam to Webcast Virtual R&D Day
December 06, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.